Akili to Speak on Integrating Digital Therapeutics Into Mainstream Healthcare at DTx West 2022
18 Febbraio 2022 - 1:00PM
Business Wire
Akili Interactive (“Akili” or the “Company”), a leading digital
medicine company pioneering the development of cognitive treatments
through game-changing technologies, today announced that Chief
Financial Officer, Santosh Shanbhag, and Vice President of
Marketing, Blake Schiller, will each participate in panel
discussions at the fifth annual DTx West event, a conference
designed to bring together leaders within digital therapeutics
(DTx) to accelerate knowledge and the advancement of DTx into
mainstream healthcare.
Shanbhag will join a panel of experts to discuss the intricacies
of mergers, acquisitions and exits unique to DTx, and the
opportunities that exist to accelerate growth of the field within
the healthcare industry. The session, “A Deep-Dive into the
Scaling-Up Strategies utilized by Digital Therapeutics Companies,”
will be moderated by Acacia Parks, Chief Behavioral Officer of
Found. DTx West attendees can tune into the panel live on
Wednesday, February 23, at 10:55 a.m. PT.
In the session, “The Intersection between Pharma and Digital
Therapeutics – Industry Insights from Both Sides,” Schiller will
explore how DTx and pharmaceutical companies can successfully work
together in ways that complement the strengths of each stakeholder
for mutually beneficial partnerships. The discussion will take
place Wednesday, February 23, at 2:40 p.m. PT.
More information on the sessions and how to attend can be found
here.
About Akili
Akili is pioneering the development of cognitive treatments
through game-changing technologies. Our approach of leveraging
technologies designed to directly target the brain establishes a
new category of medicine – medicine that is validated through
clinical trials like a drug or medical device, but experienced like
entertainment. Akili’s platform is powered by proprietary
therapeutic engines designed to target cognitive impairment at its
source in the brain, informed by decades of research and validated
through rigorous clinical programs. Driven by Akili’s belief that
effective medicine can also be fun and engaging, Akili’s products
are delivered through captivating action video game
experiences.
On January 26, 2022, Akili entered into a definitive agreement
to become publicly traded via a merger with Social Capital Suvretta
Holdings Corp. I (Nasdaq: DNAA), a special purpose acquisition
company. The transaction is expected to close in mid-2022, subject
to satisfaction of the closing conditions, after which Akili will
be listed on the Nasdaq stock market under the new ticker symbol
“AKLI.”
For more information, please visit www.akiliinteractive.com.
Additional Information and Where to Find It
In connection with the proposed business combination transaction
between Social Capital Suvretta Holdings Corp. I (“SCS”) and Akili,
SCS filed a registration statement on Form S-4 (as amended, the
“Registration Statement”) with the SEC
on February 14, 2022, which includes a preliminary prospectus and
proxy statement of SCS, referred to as a proxy
statement/prospectus. The Registration Statement has not yet become
effective. When available, a final proxy statement/prospectus will
be sent to all SCS shareholders. SCS will also file other documents
regarding the proposed transaction with the SEC. SHAREHOLDERS OF
SCS ARE ADVISED TO READ THE REGISTRATION STATEMENT, THE PROXY
STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT
WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED
TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION. Shareholders will be able to obtain free
copies of the Registration Statement, the proxy
statement/prospectus and all other relevant documents filed or that
will be filed with the SEC by SCS (when available) through the
website maintained by the SEC at http://www.sec.gov.
The documents filed by SCS with the SEC also may be obtained
free of charge at SCS’s website at
https://socialcapitalsuvrettaholdings.com/dnaa or upon written
request to 2850 W. Horizon Ridge Parkway, Suite 200, Henderson, NV
89052.
Participants in the Solicitation
SCS and Akili and their respective directors and executive
officers may be deemed to be participants in the solicitation of
proxies from SCS’s shareholders in connection with the proposed
transaction. A list of the names of such directors and executive
officers and information regarding their interests in the proposed
transaction between Akili and SCS are contained in the proxy
statement/prospectus. You may obtain free copies of these documents
as described in the preceding paragraph.
No Offer or Solicitation
This communication shall not constitute a solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the proposed transaction. This communication shall
not constitute an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any states or jurisdictions in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of such state or jurisdiction. No offering of
securities shall be made except by means of a prospectus meeting
the requirements of Section 10 of the Securities Act or an
exemption therefrom. This press release may be deemed to be
solicitation material in respect of the proposed transactions
contemplated by the proposed business combination between Akili and
SCS.
Forward-Looking Statements
This communication may contain certain forward-looking
statements within the meaning of the federal securities laws. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this communication, including but not
limited to: (i) the risk that the proposed business combination
transaction may not be completed in a timely manner or at all, (ii)
the failure to satisfy the conditions to the consummation of the
proposed transaction, including the adoption of the Merger
Agreement by the shareholders of SCS and the satisfaction of the
minimum cash condition and (iii) the occurrence of any event,
change or other circumstance that could give rise to the
termination of the Merger Agreement. The foregoing list of factors
is not exhaustive. You should carefully consider the foregoing
factors and the other risks and uncertainties described in the
“Risk Factors” section of SCS’s registration statement on Form S-4
(File No. 333-262706) filed with the SEC on February 14, 2022, and
other documents filed by SCS from time to time with the SEC. These
filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Akili and SCS assume no obligation and do not
intend to update or revise these forward-looking statements,
whether as a result of new information, future events, or
otherwise. Neither Akili nor SCS gives any assurance that either
Akili or SCS, or the combined company, will achieve its
expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220218005082/en/
Julie DiCarlo Akili Interactive julie@akiliinteractive.com
Grafico Azioni Social Capital Suvretta ... (NASDAQ:DNAA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Social Capital Suvretta ... (NASDAQ:DNAA)
Storico
Da Giu 2023 a Giu 2024